DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
Charity number: 1082702
TRUSTEES' REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
UK MYELOMA SOCIETY
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
CONTENTS
| Page | |
|---|---|
| Reference and Administrative Details of the Charity, its Trustees and Advisers | 1 |
| Trustees' Report | 2 - 7 |
| Independent Examiner's Report | 8 |
| Statement of Financial Activities | 9 |
| Balance Sheet | 10 |
| Notes to the Financial Statements | 11 - 19 |
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2023
Trustees Dr N Rabin Dr C Bygrave Dr R Hall Dr J Ashcroft Prof G Cook Dr G Pratt Dr M Kaiser Dr K Ramasamy Dr S Stern Dr R Popat Dr M Jenner Dr J Sive S Henshaw Dr S Lawless Dr R Soutar Dr S Lawson A Preston S Castell Charity registered number 1082702 Principal office Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield WF1 4DG Independent examiner Menzies LLP Chartered Accountants Richmond House Walkern Road Stevenage Herts SG1 3QP Bankers Coutts & Co 440 Strand London WC2R 0QS
Page 1
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
Trustees' Annual Re ort for the eriod p p
Period start date Period end date Day Month Year Day Month Year From 1 April 2022 To 31 March 2023
Section A Reference and administration details
Charity name UK Myeloma Society Other names charity is known by UKMS Registered charity number (if any) 1082702 Charity's principal address Dr John Ashcroft, Treasurer Dept of Haematology Pathology building Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield Postcode WF1 4DG
Names of the charity trustees who manage the charity
| 1. 2. 3. 4. 5. 6. 7. 8. |
Trustee name | Office (if any) | Dates acted if not for whole year | Name of person (or body) entitled to appoint trustee (ifany) |
|---|---|---|---|---|
| Dr Neil Rabin (London) |
Chair | January 2021 - November 2023 | ||
| Dr Ceri Bygrave (Cardiff) |
Wales Representative (Invited Board member) Chair Elect Chair from November 2023 |
November 2015 -November 2023 |
||
| Dr Rachel Hall (Bournemouth) |
Board Member/Treasurer | November 2019 -November 2023 |
||
| Dr John Ashcroft (Leeds, Mid Yorks) |
Past Chair / Teasurer | Past Chair – November 2021- November 2023 Treasurer from November 2023 |
||
| Prof Gordon Cook (Leeds) |
Past Chair/HTA lead/ College of Myeloma Dean |
November 2019- on going | ||
| Dr Guy Pratt (Birmingham) |
Secretary | November 2002-November 2023 |
||
| Dr Martin Kaiser (London) |
Board member | January 2019 – January 2025 | ||
| Dr Karthik Ramasamy (Oxford) |
Communications Lead | June 2020 - June 2025 |
TAR
2022-2023
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
| 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. |
Dr Simon Stern (Surrey) |
Guidelines Secretary | June 2020 - November 2024 | |
|---|---|---|---|---|
| Dr Rakesh Popat (London) |
Science Lead | November 2018 - November 2024 |
||
| Dr Matthew Jenner (Southampton) |
Board member | March 2019 - March 2023 | ||
| Dr Jonathan Sive (London) |
Board member | January 2020 -January 2026 | ||
| Sarah Henshaw (Nottingham) |
Myeloma Nurse Lead | November 2018 -November 2023. |
||
| Dr Sarah Lawless (N.Ireland) |
N.Ireland Representative (Invited Board member) |
January 2018 -January 2024 | ||
| Dr Richard Soutar (Glasgow) |
Scotland Representative (Invited Board member) |
January 2018 -November 2023 | ||
| Dr Shelly Lawson (Sheffield) |
Board member | January 2020 – January 2026 | ||
| Andrea Preston (Bristol) |
Board member Pharmacylead |
November 2021-November 2013 |
||
| Sophie Castell (Myeloma UK) |
Patient/Charity Representative |
January 2018-ongoing |
Names of the trustees for the charity, if any, (for example, any custodian trustees)
Name Dates acted if not for whole year
Names and addresses of advisers (Optional information)
| Type of adviser Name Address |
Type of adviser Name Address |
Type of adviser Name Address |
|---|---|---|
| Independent Examiner | Menzies LLP | Menzies LLP, Richmond House Walkern road, Stevenage, Herts, SG1 3QP |
| Bankers | Coutts & Co | 440 Strand, London, WC2R 0QS |
| Name of chief executive or names of senior staff members (Optional information) | ||
Section B Structure, governance and management
Description of the charity’s trusts
Type of governing document Constitution (eg. trust deed, constitution)
How the charity is constituted Association (eg. trust, association, company)
Trustee selection methods
Elected from membership (eg. appointed by, elected by)
TAR
2022-2023
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
Additional governance issues (Optional information)
You may choose to include additional information, where relevant, about:
-
policies and procedures adopted for the induction and training of trustees;
-
the charity’s organisational structure and any wider network with which the charity works;
-
relationship with any related parties;
-
trustees’ consideration of major risks and the system and procedures to manage them.
Section C Objectives and activities
The aims and objectives of the Society are to improve the treatment of patients with myeloma by:
Summary of the objects of the charity set out in its governing document
-
Developing and promoting clinical trials of myeloma treatment and linked scientific studies
-
• Encouraging collaborative research and innovation in myeloma • Developing guidelines for the management of patients with myeloma • Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
-
Promoting patient access to treatment through advocacy and working with stakeholders and partners
Summary of the main The UKMS had a further active year in pursuit of its’ charitable objectives which are, activities undertaken for the education, research and advocacy. public benefit in relation to these objects (include within To that end three Executive Committee meetings were held 2022; March, June and this section the statutory November. declaration that trustees In keeping with our objectives we have made significant progress in a number of key have had regard to the areas including educational meetings, guidelines and advocacy. There are summarised guidance issued by the in the following pages. Charity Commission on public benefit)
TAR
2022-2023
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
Additional details of objectives and activities (Optional information)
Revenue
You may choose to include further statements, where relevant, about:
-
policy on grantmaking;
-
policy programme related investment;
-
contribution made by volunteers.
Revenue received for corporate sponsorship contributed £129,300 (April 2022-March 2023). This re-enforces the support by pharma for the work that the UKMS undertakes. Education The Autumn Day was held on 9[th] November 2023, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was ‘Precursor states, gaps in data and resource in myeloma management’and featured Professor Paul G. Richardson from the Dana Farber Cancer Institute, Boston. Prof. Richardson presented the Michael Morley Lecture on ‘Practice-changing data from recent trials.
The Spring Day was also a virtual meeting and was held on 23[rd] March 2023. The theme for this meeting was the, ‘Personalised Therapy in Myeloma’. The plenary lecture was given by Professor Morie Gertz from the Mayo Clinic in Rochester. His talk was entitled, ‘Diagnosis and therapy of AL amyloidosis in 2023’.
Travel Bursaries A total of five travel grants for scientific conferences were awarded in 2022 to winning abstracts. Three bursaries of £1,000 each to IMS in Los Angeles in August 2022 . The IMS abstracts were presented at the Autumn Day in November 2022. Two bursaries of £1,200 covered the registration fee for ASH (American Society of Haematology Annual Meeting) in San Diego. The ASH abstracts were presented at the Spring Day in March 2023. A conference report written by the bursary recipients from ASH and IMS appeared in the e-newsletter.
| Section D | Achievements and performance |
|---|---|
| Summary of the main achievements of the charity during the year |
|
| UKMS rebranding In November 2022, the UK Myeloma Forum officially rebranded to become the UK Myeloma Society. Following a strategic review, the name change reflected the the growth of the UKMS community. A new logo and website were designed -see www.ukmyelomasociety.org.uk. Education: The annual meetings Production of two successful and well attended educational hybrid meetings in November 2022 and March 2023. For full programme details, please refer to the section above and the UKMS website. Travel Bursaries for scientific meetings The UKMS in collaboration with the Michael Morley Fund awarded a number of bursaries in 2022-23 to support the attendance of young investigators and specialist nurses at ASH Virtual (American Society of Haematology Meeting) in December 2022. Recipients of the bursaries presented their data at the UKMS Spring Day in March 2023. This is a regular and successful session. For the ASH bursary winners, recipients prepared a short review for the UKMS website and were credited in the UKMS e- newsletter. Advocacy The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm. |
TAR
2022-2023
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
Section D Achievements and erformance p
The Guidelines group The UKMS Guidelines Group, Chaired by Dr Simon Stern focused on the management of relapsed myeloma guidelines and the MGUS good practice papers for submission to BSH (British Society of Haematology).
Other guidelines were in various stages of development, notably good practice papers on MGRS and smouldering myeloma. In addition, following discussions at March’s Executive meeting, a writing group was formed to produce a good practice paper on imaging in myeloma. The aim was to produce a document that reinforced the importance of functional imaging both at diagnosis and during the later management of myeloma patients.
UKMRA - UK Myeloma Research Alliance
The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group meet virtually twice a year with one face to face meeting planned at the Wellcome Collection on 15[th] June 22. Myeloma Nurse Group The nurse group, Chaired by Sarah Henshaw have worked with MUK reviewing the Nurse Guides that are being reformatted. Projects for the next 12 months included; 1) Self-Administration of bortezomib guidance 2) Standardised treatment schedule development - this is a pharmacy group project that the nurse group has supported. 3) Working with MUK to set up nurse research plan to do a best practice guide for Peripheral Neuropathy and an audit of the positive aspect that have come out of Covid for nurses in hospitals. The group also worked with Myeloma UK to update and review the nurse guidelines. Myeloma Pharmacy Group The Pharmacy group, Chaired by Andrea Preston was newly established in 2021 and launched at the Spring Day in March 2022. The Group will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. See UKMS website for further details.
College of Myeloma (UK)
Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.
2022 fellows : Professor Kwee Yong Professor Sonja Zweegman Mr Eric Low OBE
Section E Financial review
Brief statement of the charity’s policy on reserves
The UKMS’s policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.
TAR
2022-2023
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
Details of any funds materially in deficit
Not applicable
Further financial review details (Optional information)
----- Start of picture text -----
Income
You may choose to include
Education Grants from Corporate Sponsors contributed approximately £129,300 in March
additional information,
2022 - April 2023.
where relevant about:
• the charity’s principal A £10,000 charitable contribution was made to the UKMS from the Michael Morley fund
in the year 22-23. An additional £5k in 2022 also went to support the website
sources of funds
development.
(including any
fundraising);
The Michael Morley Fund
• how expenditure has This fund is a charitable donation from a patient’s estate that is invested on behalf of the
UKMS and the interest may be used towards certain projects including supporting two
supported the key
Michael Morley lectures per annum and in 2022 to support the re-branding of the UKMS
objectives of the charity; website.
• investment policy and
Expenditure
objectives including any
Administrative costs (covering Executive meetings and associated expenses and the
ethical investment policy
salary and on-costs of our Executive Manager, accountants’ fees and employer’s liability
adopted.
insurance): £32,300.
Spring and Autumn educational meetings in the 22-23 year at approximately £22,515.
• Education Spring Day meeting March 2022 meeting approx £18,000
• UKMRA meeting June 22, Wellcome Collection £1,754
• Website costs £13,000
• Accountants annual fee £2,300
Travel Bursaries 2022
A total of five travel grants for scientific conferences were awarded in 2022 to winning
abstracts.
3 x IMS Los Angeles £1,000
2 x ASH San Diego £1,200
Reserves
The UKMF’s reserves remain sound as of 31st March 2023 and were £222,697.
----- End of picture text -----
Section F Other optional information
Section G Declaration
The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees
Signature(s) Full name(s) Dr John Ashcroft Position (eg Secretary, Treasurer Chair, etc)
Date 24-Jan-2024
TAR
2022-2023
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
INDEPENDENT AUDITORS' REPORT TO THE OF UK MYELOMA SOCIETY
Independent Examiner's Report to the Trustees of UK Myeloma Society ('the Charity')
I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2023.
Responsibilities and Basis of Report
As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').
I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
Independent Examiner's Statement
Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.
I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
-
accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Signed: Stuart Cuzner
Dated: 25-Jan-2024 FCCA ACA
Menzies LLP
Chartered Accountants Richmond House Walkern Road Stevenage Herts SG1 3QP
Page 8
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2023
| Note Income from: Donations and legacies 3 Investments 4 Total income Expenditure on: Raising funds 5 Charitable activities 6 Total expenditure Net income before net (losses)/gains on investments Net (losses)/gains on investments 11 Net movement in funds Reconciliation of funds: Total funds brought forward Net movement in funds Total funds carried forward |
Unrestricted funds 2023 £ 131,251 5,775 137,026 1,536 94,941 96,477 40,549 (12,040) 28,509 469,680 28,509 498,189 |
Total funds 2023 £ 131,251 5,775 137,026 1,536 94,941 96,477 40,549 (12,040) 28,509 469,680 28,509 498,189 |
Total funds 2022 £ 121,320 4,285 125,605 |
|---|---|---|---|
| 1,633 72,984 74,617 |
|||
| 50,988 3,863 54,851 |
|||
| 414,829 54,851 469,680 |
The Statement of Financial Activities includes all gains and losses recognised in the year.
The notes on pages 11 to 19 form part of these financial statements.
Page 9
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
BALANCE SHEET AS AT 31 MARCH 2023
| Note Fixed assets Investments 11 Current assets Debtors 12 Cash at bank and in hand Creditors: amounts falling due within one year 13 Net current assets Total assets less current liabilities Net assets excluding pension asset Total net assets Charity funds Restricted funds Unrestricted funds Designated funds General funds Total unrestricted funds 14 Total funds |
2,799 312,278 315,077 (8,380) 275,492 222,697 |
2023 £ 191,492 191,492 306,697 498,189 498,189 498,189 - 498,189 498,189 |
8,199 248,241 256,440 (11,477) 283,717 185,963 |
2022 £ 224,717 |
|---|---|---|---|---|
| 224,717 244,963 |
||||
| 469,680 | ||||
| 469,680 | ||||
| 469,680 | ||||
| - 469,680 |
||||
| 469,680 |
The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:
................................................
Dr J Ashcroft
(Trustee)
24-Jan-2024 Date:
The notes on pages 11 to 19 form part of these financial statements.
Page 10
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
1. General information
UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the defination of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.
2. Accounting policies
2.1 Basis of preparation of financial statements
The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.
The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.
UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.
2.2 Going concern
At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
2.3 Income
All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.
Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.
Dividends arising on equity investments are accounted for in the year they are due and receivable.
Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.
2.4 Expenditure
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.
Page 11
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
2. Accounting policies (continued)
2.4 Expenditure (continued)
Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.
Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.
All expenditure is inclusive of irrecoverable VAT.
2.5 Interest receivable
Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.
2.6 Investments
Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as ‘Gains/(Losses) on investments’ in the Statement of Financial Activities.
Investments held as fixed assets are shown at cost less provision for impairment.
2.7 Financial instruments
The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.
2.8 Pensions
The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.
2.9 Fund accounting
General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.
Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.
Investment income, gains and losses are allocated to the appropriate fund.
Page 12
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
3. Income from donations and legacies
| Donations Total 2022 |
Unrestricted funds 2023 £ 131,251 121,320 |
Total funds 2023 £ 131,251 121,320 |
Total funds 2022 £ 121,320 |
|---|---|---|---|
4. Investment income
| Income from listed investments Interest receivable Total 2022 |
Unrestricted funds 2023 £ 5,351 424 5,775 4,285 |
Total funds 2023 £ 5,351 424 5,775 4,285 |
Total funds 2022 £ 4,275 10 4,285 |
|---|---|---|---|
5. Raising funds
| Investment management fees Total 2022 |
Unrestricted funds 2023 £ 1,536 1,633 |
Total funds 2023 £ 1,536 1,633 |
Total funds 2022 £ 1,633 |
|---|---|---|---|
Page 13
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
6. Analysis of expenditure on charitable activities
Summary by fund type
| Forum expenses Website costs Service charges Staff costs (see note 9) Accountancy (see note 8) Total 2022 |
Unrestricted funds 2023 £ 45,907 13,445 3,333 29,976 2,280 94,941 72,984 |
Total 2023 £ 45,907 13,445 3,333 29,976 2,280 94,941 72,984 |
Total 2022 £ 34,177 - 2,814 29,819 6,174 72,984 |
|---|---|---|---|
7. Analysis of expenditure by activities
| Forum expenses Website costs Service charges Staff costs (see note 9) Accountancy (see note 8) Total 2022 |
Activities undertaken directly 2023 £ 45,907 13,445 3,333 - - 62,685 36,991 |
Support costs 2023 £ - - - 29,976 2,280 32,256 35,993 |
Total funds 2023 £ 45,907 13,445 3,333 29,976 2,280 94,941 72,984 |
Total funds 2022 £ 34,177 - 2,814 29,819 6,174 72,984 |
|---|---|---|---|---|
Page 14
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
8. Independent examiner's remuneration
| 2023 | 2022 | |
|---|---|---|
| £ | £ | |
| Fees payable to the Company independent examiner for the independent | ||
| examination of the Company's annual accounts | 2,280 | 2,640 |
| Fees payable to the Charity's independent examiner in respect of: | ||
| Accountancy services for the Charity | - | 3,534 |
9. Staff costs
| Wages and salaries Pension costs |
2023 £ 29,049 927 29,976 |
2022 £ 29,151 668 |
|---|---|---|
| 29,819 |
The average number of persons employed by the Charity during the year was as follows:
| 2023 | 2022 | |
|---|---|---|
| No. | No. | |
| Administration | 1 | 1 |
No employee received remuneration amounting to more than £60,000 in either year.
Key management personnel are the trustees and they received no remuneration during the current or prior year.
10. Trustees' remuneration and expenses
During the year, no Trustees received any remuneration or other benefits (2022 - £NIL) .
During the year ended 31 March 2023, expenses totalling £ 933 were reimbursed to 9 Trustees (2022 - £1,919 to 9 Trustees).
Page 15
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
11. Fixed asset investments
| Cost or valuation At 1 April 2022 Additions Disposals Revaluations Transfers Management fees Dividend and interest income At 31 March 2023 Net book value At 31 March 2023 At 31 March 2022 12. Debtors Due within one year Other debtors Prepayments and accrued income |
Listed investments £ 208,723 7,532 (19,308) (9,404) - - - 187,543 187,543 208,723 |
Cash portfolio £ 15,994 (7,532) 16,672 - (25,000) (1,536) 5,351 3,949 3,949 15,994 2023 £ 2,799 - |
Total £ 224,717 - (2,636) (9,404) (25,000) (1,536) 5,351 191,492 191,492 224,717 2022 £ 2,799 5,400 |
||
|---|---|---|---|---|---|
| 2,799 | 8,199 |
13. Creditors: Amounts falling due within one year
| Trade creditors Pension fund loan payable Other creditors Accruals and deferred income |
2023 £ 6,150 130 - 2,100 8,380 |
2022 £ - - 4,428 7,049 |
|---|---|---|
| 11,477 |
Page 16
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
| 14. Statement of funds Statement of funds - current year Designated funds Michael Morley Investment Fund General funds General Funds Total Unrestricted funds |
Balance at 1 April 2022 £ 283,717 185,963 469,680 |
Income £ 5,351 131,675 137,026 |
Expenditure £ (1,536) (94,941) (96,477) |
Gains/ (Losses) £ (12,040) - (12,040) |
Balance at 31 March 2023 £ 275,492 |
|---|---|---|---|---|---|
| 222,697 | |||||
| 498,189 |
Page 17
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
| 14. Statement of funds (continued) Statement of funds - prior year Designated funds Michael Morley Investment Fund General funds General Funds Total Unrestricted funds |
Balance at 1 April 2021 £ 277,212 137,617 414,829 |
Income £ 4,275 121,330 125,605 |
Expenditure £ (1,633) (72,984) (74,617) |
Gains/ (Losses) £ 3,863 - 3,863 |
Balance at 31 March 2022 £ 283,717 |
|---|---|---|---|---|---|
| 185,963 | |||||
| 469,680 |
The designated fund is used to hold the Charity's investments and generate income.
Page 18
DocuSign Envelope ID: E8E4ABBC-5E98-4FF6-9007-D33C80390146
UK MYELOMA SOCIETY
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023
15. Analysis of net assets between funds
Analysis of net assets between funds - current year
| Fixed asset investments Current assets Creditors due within one year Total |
Unrestricted funds 2023 £ 191,492 315,077 (8,380) 498,189 |
Total funds 2023 £ 191,492 315,077 (8,380) 498,189 |
|---|---|---|
Analysis of net assets between funds - prior year
| Fixed asset investments Current assets Creditors due within one year Total |
Unrestricted funds 2022 £ 224,717 256,440 (11,477) 469,680 |
Total funds 2022 £ 224,717 256,440 (11,477) 469,680 |
|---|---|---|
16. Related party transactions
There were no disclosable related party transactions during the year (2022 - none).
Page 19